Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX), Siemens Healthineers AG (SEMHF) and Sesen Bio (SESN).
Neurocrine (NBIX)
In a report released today, Alan Carr from Needham assigned a Hold rating to Neurocrine. The company’s shares closed last Monday at $123.01.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.0% and a 42.6% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $139.56 average price target, a 14.3% upside from current levels. In a report issued on July 20, Credit Suisse also maintained a Hold rating on the stock with a $135.00 price target.
See today’s analyst top recommended stocks >>
Siemens Healthineers AG (SEMHF)
In a report released today, Holger Fechner from Norddeutsche Landesbank maintained a Buy rating on Siemens Healthineers AG, with a price target of EUR52.00. The company’s shares closed last Monday at $47.90.
According to TipRanks.com, Fechner is ranked #4930 out of 6850 analysts.
Currently, the analyst consensus on Siemens Healthineers AG is a Hold with an average price target of $50.51, which is a 5.6% upside from current levels. In a report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a EUR52.00 price target.
Sesen Bio (SESN)
In a report released yesterday, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Sesen Bio, with a price target of $2.25. The company’s shares closed last Monday at $1.06.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.5% and a 36.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.
Currently, the analyst consensus on Sesen Bio is a Moderate Buy with an average price target of $3.63, which is a 233.0% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.